There have been limited anatomic and physiological investigations of the female sexual arousal response. A broader understanding of the physiologic mechanisms of female sexual arousal function is required to improve the management of women with sexual dysfunction. Three experimental test systems have been developed to understand better the biochemical and physiological mechanisms of female sexual arousal response. An in vivo animal model was developed to record physiological and hemodynamic changes in the clitoris and vagina following pelvic nerve stimulation and administration of vasoactive agents and physiological modulators. In vitro organ baths of clitoral and vaginal tissue were utilized to investigate mechanisms involved in the regulation of smooth muscle contractility. In addition, primary cell cultures of human and animal clitoral and vaginal smooth muscle cells were developed to investigate signal transduction pathways modulating smooth muscle tone. In vivo studies revealed hemodynamic changes in vagina and clitoris in response to pelvic nerve stimulation, vasodilators and physiological modulators. Organ bath studies have demonstrated that clitoral and vaginal smooth muscle tone is affected by non-adrenergic and non-cholinergic neurotransmitters, and the presence of functional alpha 1 and alpha 2 adrenergic receptors in these tissues has been established through biochemical studies. These changes are regulated by the tone of vascular and non-vascular smooth muscle in the vagina and clitoris. Primary cell culture studies have suggested that several physiological modulators such as vasoactive intestinal polypeptide (VIP), nitric oxide (NO), and prostaglandin E (PGE) regulate vaginal smooth muscle contractility. Data from experimental models have provided a preliminary understanding of the mechanisms of the female sexual arousal response.
Introduction
Female sexual dysfunction is a highly prevalent, multi-causal and multi-dimensional disorder, which results in signi®cant personal distress, adversely impacting on life quality and interpersonal relationships. Current epidemiological data reveal that up to 43% of women have some type of sexual dysfuntion. 1 Approximately 10 million American women aged 50 ± 74 y self-report complaints of diminished vaginal lubrication, pain and discomfort with intercourse, decreased arousal, and dif®culty achieving orgasm. Laumann et al 1 found that sexual dysfunction is more prevalent in women than in men, and is associated with various psychodemographic characteristics such as age, education, and poor physical and emotional health. More importantly, female sexual dysfunction is associated with negative sexual relationship experiences.
In 1966 Masters and Johnson 2 ®rst characterized the female sexual response as consisting of four successive phases: excitement, plateau, orgasm and resolution. Eight years later, Kaplan 3 introduced the concept of`desire' as the ®rst phase of the sexual response cycle, followed by arousal and orgasm. 6 Kaplan's 3-phase model is the basis for the consensus classi®cation system developed by the American Foundation of Urologic Disease (AFUD) Consensus Panel in October 1998. 4 Based on this consensus panel, sexual arousal disorder is de®ned as the persistent or recurring inability to attain, or maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement, which causes marked distress or interpersonal dif®culty. It may be experienced as lack of subjective excitement or lack of genital lubricationaswelling or other somatic responses.
Genital arousal responses
There have been a limited number of investigations of the central and peripheral mechanisms of female sexual function. 5 ± 12 There is a need to expand the current understanding of the mechanisms of female sexual function and dysfunction to improve clinical management. Investigation of the physiologic and biochemical pathways of female sexual arousal requires an integrated approach which combines functional studies of isolated tissues in organ baths, biochemical studies in intact human and animal clitoral and vaginal smooth muscle cells, and in vivo models. These models can then be used to assess the ef®cacy of vasoactive agents as well as the role of hormones on the modulation and regulation of genital arousal.
Results from in vivo animal studies
In order to evaluate female genital arousal response, an animal model, using female New Zealand White rabbits, was developed. The changes in vaginal and clitoral hemodynamics in response to pelvic nerve stimulation were recorded. 10 The authors noted that pelvic nerve stimulation caused a 236% increase in vaginal blood¯ow, a 198% increase in vaginal wall pressure, a 114% increase in vaginal length, a 154% increase in clitoral intracavernosal pressure and a 197% increase in clitoral blood¯ow. Vaginal luminal pressure, as measured by balloon catheter in the vaginal canal, decreased with pelvic nerve stimulation. Injection of papaverine hydrochloride and phentolamine mesylate into the vaginal spongy muscularis layer increased vaginal wall pressure and vaginal blood¯ow, whereas injection of saline did not change vaginal wall pressure or blood¯ow.
To record changes in genital tissue engorgement following pelvic nerve stimulation, we utilized a non-invasive continuous wave optical spectrometry laser oximeter. The device consists of a ®ber optic array probe with one detector and eight light sources capable of emitting light in the near infrared spectrum and assessing changes in the fraction of blood oxyhemoglobin and deoxyhemoglobin ( Figure  1 ) over time. The probe has been used to measure the hemodynamic changes of the vagina and clitoris in response to pelvic nerve stimulation. A rise in the fraction of oxyhemoglobin and decrease in the fraction of deoxyhemoglobin is observed in response to pelvic nerve stimulation. In addition, a frequency-dependent response to pelvic nerve stimulation has been documented. 13 These observations suggest that increased genital blood¯ow is mediated by pelvic nerve stimulation and are consistent with data reported by Park et al. 10 The effects of several vasoactive agents and the phosphodiesterase type 5 inhibitor sildena®l were studied. Following pelvic nerve stimulation, the tissue hemoglobin content of the genital tissues increased signi®cantly after intravenous injection of sildena®l compared with control. In addition, the duration of the increased blood¯ow response was signi®cantly prolonged following sildena®l administration compared with saline. 13 These data suggest that the NO-cGMP pathway is involved in the physiological mechanism of female genital sexual arousal, and, further, that sildena®l facilitates female genital sexual arousal.
Given that the vagina is richly innervated with VIP immunoreactive ®bers, it is postulated that VIP plays an important role in regulating smooth muscle relaxation and the hemodynamics associated with sexual arousal in the vagina. Intravaginal administration of VIP alone increased oxyhemoglobin and total hemoglobin concentration in genital tissue as much as pelvic nerve stimulation (unpublished data). Pelvic nerve stimulation after intravaginal injection of VIP caused a signi®cant increase in genital oxyhemoglobin and total hemoglobin concentration as compared with pelvic nerve stimulation without VIP. These observations suggest that increases in genital blood¯ow are modulated in part by VIP-mediated nerves.
In female genital tissue the adrenergic pathway may be involved in maintenance of the quiescent Figure 1 Representative laser oximetry recording indicating parameters that were measured to assess changes in tissue hemoglobin concentration. Amplitude was de®ned as the change in hemoglobin concentration between the baseline and peak value. Response duration was de®ned as the time between the initiation of pelvic nerve stimulation (PNS) and the return to baseline. The pelvic nerve was stimulated for 30 s. 
Studies in organ baths
Understanding local regulatory mechanisms which modulate clitoral erectile tissue and vaginal muscularis smooth muscle tone is necessary to perform physiological studies of the arousal phase of the female sexual response. The presence of nerve ®bers containing neuropeptide Y (NPY), VIP, NOS, calcitonin gene-related peptide (CGRP) and substance P has been con®rmed in human vaginal tissues using immunohistochemical techniques. 14 Although previous studies 9, 15, 16 have suggested that VIP may be involved in the regulation of clitoral and vaginal smooth muscle tone, no conclusive experimental evidence of VIP's functional involvement has been forthcoming.
The role of the alpha adrenergic system in the female sexual arousal phase has been previously documented. 7, 8 Clonidine, an alpha 2 adrenergic agonist, has been shown to impair vaginal engorgement and lubrication when administered to healthy volunteers. 8 Organ bath chamber studies to assess clitoral and vaginal tissue responses to electric ®eld stimulation, alpha adrenergic agonists, NO donors, and VIP have been performed at our institution. Electrical ®eld stimulation (EFS) induced a biphasic (contractionarelaxation) response in clitoral and vaginal tissue strips. A dose-dependent contraction in vaginal and clitoral tissues wasobservedaftertheadministrationof norepinephrine. Bretylium, an inhibitor of NE release, diminished the contractile response inducedby EFS in both tissues (unpublished data).
Using speci®c molecular probes and RNAase protection assays, mRNA for both alpha 1a and alpha 2a adrenergic receptors in human clitoral and vaginal smooth muscle cells has been detected. 17 These observations suggest that adrenergic nerves mediate part of the contractile response in vaginal and clitoral tissues. The role of endothelin, NPY, angiotensin, eicosanoids and other vasoconstrictor agents in the regulation of smooth muscle tone in these tissues remains to be determined.
Sodium nitroprusside caused a dose-dependent relaxation of vaginal and clitoral strips precontracted with norepinephrine. Clitoral tissue relaxation was inhibited by L-nitro-arginine, the nitric oxide synthase inhibitor, and enhanced by Larginine. In contrast, L-nitro-arginine or L-arginine did not signi®cantly affect EFS-induced relaxation in vaginal tissue strips (unpublished data). These observations suggest that non-adrenergic, noncholinergic (NANC) nerves may modulate clitoral and vaginal smooth muscle tone.
Clitoral and vaginal tissue strips contracted with norepinephrine and subjected to EFS exhibited frequency-dependent relaxation, and relaxed to exogenously added VIP and NO, although VIP was more ef®cacious in relaxing vaginal tissue than clitoral tissue (unpublished data). However, in the absence of active VIP receptor antagonists, it remains dif®cult to evaluate the role of VIP in the modulation of vaginal smooth muscle contractility. Multiple physiologic mediators are probably involved in regulating vaginal and clitoral smooth muscle tone. The list of such mediators will become larger as more physiological and biochemical studies are undertaken in these tissues. 
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Studies in cell culture
Human and rabbit vaginal smooth muscle cells have been sub-cultured and characterized, allowing investigation of the synthesis of second messenger cyclic nucleotides in response to vasodilators and determination of the activity and kinetics of phosphodiesterase (PDE) type 5. 17 Cultured vaginal cells exhibited growth patterns typical of smooth muscle cells and immunostained with antibodies against alpha smooth muscle actin. These cells also retained functional prostaglandin E, VIP and beta adrenergic receptors, as demonstrated by increased intracellular cAMP synthesis in response to PGE1, VIP or isoproterenol. The response to these vasoactive substances was augmented with forskolin, suggesting stabilization of G-protein-activated adenyl cyclases. Treatment with sodium nitroprusside in the presence of sildena®l enhanced intracellular synthesis and accumulation of cGMP. Incubation of rabbit vaginal tissue with sildena®l, sodium nitroprusside, and PGE1 or forskolin produced a marked increase in intracellular cGMP. These observations were similar to ®ndings in cultured cells and suggest that sub-cultured cells retained functional characteristics exhibited in intact tissue. The cells retained PDE type 5 expression as shown by speci®c cGMP hydrolytic activity. Sildena®l and zaprinast inhibited cGMP hydrolysis competitively and bound with high af®nity (inhibition constants K i 7 and 250 nM, respectively).
These observations suggest that cultured human and rabbit vaginal smooth muscle cells retained their metabolic functional integrity, allowing the investigation of the nitric oxide pathway and the role of PDE type 5 inhibitors in vaginal smooth muscle tone.
Role of clitoral and vaginal smooth muscle tone in regulating tissue hemodynamics
In response to neurogenic stimulation, clitoral and vaginal smooth muscle tone decreases, allowing for increased blood¯ow, increased vasocongestion and vaginal and clitoral engorgement. Thus, genital smooth muscle tone appears to regulate the changes in genital hemodynamics and genital arousal. Preliminary studies in organ baths have shown that the contractility of clitoral and vaginal smooth muscle cells is modulated by the alpha adrenergic neurotransmitter, norepinephrine. The contractile response of the smooth muscle cells is mediated by both alpha 1 and alpha 2 adrenergic receptors. Electrical ®eld stimulation studies suggest that NO plays a key role in clitoral smooth muscle contractility. Clitoral and vaginal tissue strips relaxed to exogenous NO donor, suggesting a functional NOacGMP pathway. Both tissues also relaxed to exogenous VIP, suggesting that multiple physiological dilators may be integrated in the overall pathway of vaginal and clitoral smooth muscle relaxation in response to neural and vasodilator stimulation.
Role of hormones in female sexual arousal disorder
The role of estrogens in the maintenance and function of the female genitalia has been well documented. 18 ± 21 The thickness of the vaginal wall, the degree of rugae and vaginal lubrication have all been shown to be estrogen-dependent. 20 In the estrogen-de®cient state, the vaginal wall is thinner and more susceptible to trauma with a decreased ability to heal, as well as drier and less acidic, with an increased vulnerability to infection. 21 Estrogen replacement has been shown to enhance genital sensation and improve vaginal lubrication in addition to enhancing blood¯ow in post-menopausal women. 18, 19 Estrogens may be important in maintaining the integrity of vaginal and clitoral smooth muscle function by regulating smooth muscle cell growth in the vagina and the clitoris, connective tissue metabolism and nitric oxide synthesis.
While investigation of the physiological and biochemical mechanisms of female sexual arousal function necessitates the use of animal models, it must be recognized that the ability to extrapolate data obtained from these models to the human condition may be limited. The endocrine and reproductive differences between humans and animals cannot be ignored. While the length of the menstrual cycle in women is 28 ± 30 days, the rabbit does not exhibit such a cycle. In women, the luteal phase takes place regardless of the occurrence of coitus, with ovulation occurring approximately 14 days prior to the onset of menses. In the rabbit, the luteal phase takes place only after coitus, with ovulation occurring 10 hours post-coitus. Nevertheless, the female rabbit model circumvents potentially confounding variables associated with different stages of the menstrual cycle compared with other animal models that exhibit various occurrences and duration of estrus phases. Estrogen levels are expected to be consistently high in the rabbit. Valuable information may, however, be obtained from animal models investigating the physiological and biochemical mechanisms involved in the regulation of vaginal and clitoral hemodynamics during estrogen deprivation and estrogen replacement. Studies in the animal model should advance our understanding concerning modulation of the female sexual arousal response by both estrogen and androgen hormones as well as by various vasoactive agents. 
Future directions
Future work should aim to delineate the role of neurogenic mechanisms in clitoral and vaginal engorgement, vasocongestion and vaginal lubrication. This work must identify the neural mechanisms which regulate contractility in clitoral and vaginal smooth muscle. Biochemical studies will identify the post-junctional receptors for the several neurotransmitters which act upon the genital tissue. This will lead to the investigation of the signal transduction pathways underlying the receptor and post-receptor mechanisms involved in regulation of clitoral and vaginal smooth muscle tone. Through these biochemical studies, the role of the different receptor systems in the regulation of genital arousal will be clari®ed. In vitro studies will continue to delineate the physiological mechanisms involved in the female sexual response, and in vivo studies will expand the understanding of the physiologic and biochemical mechanisms tested in the in vitro system. Estrogen, progestin and testosterone are involved in differentiation, growth and maintenance of clitoral and vaginal tissue function. Studies on the effects of hormones in vaginal and clitoral tissues are critical to understanding the physiological and pathophysiological mechanisms involved in the female sexual arousal response in various endocrine states. The results of such studies will be improved female sexual health management strategies for women suffering from sexual arousal dysfunction, especially in the menopause.
Conclusion
Female sexual dysfunction is a prevalent and signi®cant health disorder. In order to better diagnose and treat women with this problem, a clear de®nition and understanding of the physiology and pathophysiology of the dysfunction is necessary. To this end, several laboratory studies including in vivo animal models, organ bath chambers and cell cultures have been developed to study the role of various neurotransmitters, vasoactive agents and endocrine hormones. It must not be forgotten that these physiological responses re¯ect only a part of the full and complex realm of factors forming the complete female sexual response.
